Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Abstract

Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

Statistics

0100200200920102011201220132014201520162017
Citations per Year

201 Citations

Semantic Scholar estimates that this publication has 201 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hanauer2007RisksAB, title={Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?}, author={Stephen B. Hanauer}, journal={Gut}, year={2007}, volume={56 9}, pages={1181-3} }